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Summary 
The liver of C57BL/6 mice contains a major subset of CD4+8 -  and CD4-8- T  cell receptor 
(TCR)-cx/[3  +  cells  expressing the  polymorphic natural  killer NKI.1  surface marker.  Liver 
NK1. I+TCR-ot/[3 + (NK1 + T) cells require interaction with [32-microglobulin-associated, ma- 
jor histocompatibility complex class I-like molecules on hematopoietic cells for their develop- 
ment and have a TCR repertoire that is highly skewed to V[38.2,  V[37, and V[32. We show 
here that congenic C57BL/6.V[3  ~ mice, which lack V[38-expressing T  cells  owing to a ge- 
nomic deletion at the V[3 locus, maintain normal levels of liver NK1 + T  cells owing to a dra- 
matic increase in the proportion of cells expressing V[37 and V[32 (but not other V[3s), More- 
over, in C57BL/6 congenic TCK-V[33 and -V[38.1  transgenic mice (which in theory should 
not express other V[3, owing to allelic  exclusion at the  TC1L-[3  locus), endogenous TCR- 
V[38.2, V[37, and V[32 (but not other V[3s) are frequently expressed on liver NKI+T cells but 
absent on lymph node T  cells. Finally, when endogenous V[3 expression is prevented in TCR- 
V[~3 and V[38.1 transgenic mice (by introduction of a null allele at the C[3 locus), the develop- 
ment  of liver  NKI+T  cells  is  totally  abrogated.  Collectively,  our  data  indicate  that  liver 
NKI+T cells have a stringent requirement for expression of TCR-V[38.2, V[37,  or V[32 for 
their development. 
A 
mature  T  cell  subset  comprising  CD4+8 -  and 
CD4-8- double'negative (DN) TCR-oJ[3 + cells ex- 
pressing the polymorphic NKI.1 marker has been demon- 
strated to reside in thymus, bone marrow, spleen, and liver of 
appropriate  mouse  strains  (reviewed  in  references  1-3). 
NK1.1 + TCR-ot/[3 + (NK1 + T) cells have a restricted usage 
of TCK-V[3 genes (mainly V[38.2, V[37, and V[32) and re- 
quire [32-microglobulin ([32m)-associated (MHC class I-like) 
molecules  on  hematopoietic  cells  for their  development. 
Other characteristics  ofNK1 + T cells are well studied, espe- 
cially  in  thymus.  They have  a  potential  to  secrete  large 
amounts of IL-4 and  IFN-~  upon primary stimulation in 
vitro and in vivo, and freshly isolated NK1 + T  cells can di- 
rectly kill CD4+8 + thymocytes via the Fas pathway.  IL-7 
seems to induce a preferential expansion ofNK1 + T cells in 
normal but not in [32m-deficient  mice. DN NK1 + T  cells 
were originally proposed as a possible source of  lymph node 
DN  T  cells  in  autoimmune  Ipr/Ipr mice.  Although  both 
populations are absent in [~2  m-/- mice, they seem to belong 
to different lineages,  because lpr DN T  cells undergo nega- 
tive  selection  mediated  by  endogenous  superantigens, 
whereas DN  NK1 +  T  cells  do  not.  Most  recently it  has 
been reported that thymic NK1 + T cells predominantly use 
an invariant ot chain, Vcx14-Ja281  (4), suggesting an inter- 
action with a restricted set ofligands. 
Since NK1 + T  cells preferentially use V[38.2,  V[37, and 
VI32 gene segments in normal mice, we have investigated 
whether  they  formally  require  these  V[3s, by  three  ap- 
proaches.  First,  we  studied  congenic  C57BL/6  (B6).VI3  ~ 
mice, which express the NKI.1 marker and have no V[~8  + 
T  cells, owing to genomic deletion of the V[38 locus. Liver 
NK1 + T  cells in these mice were present at normal levels 
and expressed either V[37 or V[32 but not other V[3s. Sec- 
ond, analysis of TCR-V[33 and -V[38.1  transgenic mice on 
a B6 background revealed that liver NK1 + T  cells  selec- 
tively expressing endogenous V[38.2,  V[37,  and V[32  (but 
not other V[3s) still  can arise.  Finally, we  derived TCR- 
V[33 and -V[38.1  transgenic mouse strains unable to express 
endogenous V[3 chains by backcrossing them to TCR-[3  -/- 
mice that have a homozygous deletion encompassing both 
C[3 genes (5). NK1 + T  cells were totally absent in the liver 
of these mice, whereas conventional T  cells developed nor- 
really. Collectively, our data demonstrate a stringent TC1L- 
V[3 requirement for the development of  liver NK1 + T cells. 
Materials and Methods 
Mice.  B6 mice were purchased from Harlan Olac  (Bicester, 
UK). Congenic B6.V[3  a mice (a kind gift of Dr. A. Livingstone, 
Basel Institute for Immunology, Basel, Switzerland) were derived 
by transferring the V[3  ~ haplotype (which has an extensive dele- 
tion at the TCK-13 locus, including V[~5, 8, 9,  11,  12, and  13 
gene segments [6]) from C57L (H-2  b, V[3  a) to B6 mice  (H-2  b, 
v[3b). The B6.V[3  ~  mice used were backcrossed for 15 generations 
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ground were  kindly provided by Dr.  M.  Dohlsten  (Pharmacia 
Biotech, Lurid, Sweden) and Dr. H. Pircher (University Hospital, 
Zurich, Switzerland). TC1K-V[33 and -V[38.1 transgenic mice lack- 
ing endogenous V[3 expression were obtained by backcrossing to 
TCR-[3 -/-  mice  (The Jackson  Laboratory, Bar  Harbor,  ME), 
which are homozygous for a deletion in the TCR C[3 locus (5). 
F2 progeny were typed for expression of transgenic and/or en- 
dogenous TCIK-~ chains by staining of PBLs  with appropriate 
anti-VI3 mAbs. All mice were used between 2 and 5 months of  age. 
Cell Preparation.  To obtain liver mononuclear cells (MNCs), the 
liver was pressed through a stainless steel mesh and suspended in 
50 ml of PBS  (9). After being washed once with PBS, the cells 
(including MNCs and hepatocytes) were fractionated by discon- 
tinuous (40% and 80%) Percoll gradient centrifugation for 10 min 
at 900 g. The interface was harvested, washed with 5% FCS PBS, 
and used for experiments. MNCs  from lymph nodes were  ob- 
tained by a standard method. 
Antibodies and Flow Cytometric Analysis.  The  following  mAb 
conjugates were used in this study: H57-597-PE  (anti-TCR-13; 
Caltag Laboratories, San  Francisco, CA); GK1.5-PE  (anti-CD4; 
Becton Dickinson and Co., Mountain View, CA); PK136-biotin 
(anti-NKl.1; Pharmingen,  San Diego,  CA).  F23.1-FITC  (anti- 
V[38.1-8.3), F23.2-FITC (anti-V[38.2), and 44-22-FITC (and-V[36) 
were prepared in our laboratory. Unconjugated KJ16  (anti-V[38.1/ 
8.2), TIK310 (anti-V[~7), KJ25 (anti-V[33), and B20.6.5 (anti-V[52) 
were developed with FITC-conjugated goat anti-rat IgG (Caltag 
Laboratories) or goat anti-mouse IgG and lgM (Tago, Inc., Burl- 
ingame, CA). Kat or mouse Ig was used to block free Ig sites be- 
fore addition of streptavidin Tri-color and analyzed by FACScan 
using the Lysis II program (Becton Dickinson and Co.) To detect 
co-expression of [3  T (V[33) and [3  E (V[38) on liver CD4+NK1 + T 
cells of TCK-V[33  transgenic mice, four-color flow cytometric 
analysis was performed. Unconjugated KJ25  (anti-[3T) was devel- 
oped with PE-conjugated goat F(ab')2 anti-mouse IgG (Caltag 
Laboratories), mouse Ig was used to block, and F23.1-FITC (anti- 
[3E),  PK136-biotin,  and  GK1.5-1Ked613  (GIBCO  B1KL [Life 
Technologies, Inc.], Gaithersburg, MD) were added. The biotin- 
ylated reagent  was  revealed with  streptavidin-aUophycocyanin 
(Caltag Laboratories). Samples were analyzed with a FACStar Plus 
equipped with the Lysis II program (Becton Dickinson and Co.). 
Results and Discussion 
We first compared the proportion of total NK1 + T  cells, 
CD4+NK1 +  T  cells,  and  TCR-V[3  usage  among  CD4 + 
NK1 + T  cells in the livers of normal B6 mice and congenic 
B6.V[3 a mice  (Fig.  1  and Table  1).  As expected from our 
previous study (9), liver CD4+NK1 + T  cells of control B6 
mice express V[38  (69.3  +  3.4%), V~7  (14.4  -+  1.7%),  and 
V[32(8.1  +  0.4%)  at  much  higher levels when  compared 
with lymph node CD4 + T  cells (22.1  +  2.5%,  1.8  +  0.3%, 
and  6.5  +  0.8%,  respectively).  Other  V[3s  were  virtually 
absent in liver CD4+NK1 +  T  cells (reference 9;  data not 
shown).  In congenic B6.V[3 a mice, a  normal frequency of 
liver NK1 + T  cells and CD4+NK1 + T  cells was observed 
as compared with that in B6 mice, despite the total absence 
of V[38 + cells (<1%). Instead, B6.v[3a liver CD4+NK1 + T 
cells use V[37 (46.2  -+ 5.7%) and V[32 (47.1  -+ 3.6%) much 
more  frequently  than  cells from  normal  mice;  however, 
they do not express V[36, V[33, V[34, and V[310, which are 
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Figure 1.  (A) Proportion of total and CD4+NK1 + T cells in liver of 
B6 and B6.VI3  ~  mice. Liver MNCs were stained with H57-597-PE (anti- 
TCR-I3) or GK1.5-PE (anti-CD4) and PK136-biotin (anti-NKl.1)  plus 
streptavidin Tri-color.  One  representative experiment  is shown. The 
numbers correspond to the population of total or CD4+NK1 + T cells in 
each strain. (B) V[3 expression of liver CD4+NK1 + T  cells in B6 and 
B6.V[3  ~  mice. Liver MNCs were stained with the indicated FITC-conju- 
gated  anti-VI3 mAbs followed by  GK1.5-PE  and  PK136-hiotin  plus 
streptavidin Tri-color. Histograms are gated on CD4+NK1 § T cells. 
not deleted in B6.VI3  a mice (data not shown). Lymph node 
CD4 + T  cells in B6.V[3 ~ mice used V137 (3.0  -+ 0.7%)  and 
V132 (14.0  +  3.6%)  at moderately higher levels than in B6 
mice, presumably owing to  the  absence of several V[3s  in 
this haplotype (6). Thus, liver CD4+NK1 §  T  cells seem to 
require TCR,-VI38.2, VI37, or VI32 for development, since 
other VI3s cannot substitute for V138.2  in B6.VI3  ~ mice. 
To further confirm the stringency of the VI3 requirement 
for development officer NK1 + T  cells, we also investigated 
NK1 + T  cells in the liver of TCR-VI33 and -V138.1  trans- 
genic mice (Fig. 2 A  and Table 2). As expected, most lymph 
node CD4 + T  cells ofV[33 transgenic mice (95.4  -+ 0.9%) 
expressed  transgenic  V133 03T),  whereas  endogenous  Vt3s 
(13E) such  as  V138, V[37,  V[32,  and V[36  were  very rare.  In 
liver, the proportions  of both  total NK1 §  T  cells  (7.8  + 
0.9%)  and CD4+NK1 + T  cells (4.6  -+ 0.6%) were reduced 
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and Lymph Node CD4 + T cells of B6 and B6. V~8  a Mice 
Liver CD4+NK1 +  LN CD4 + 
V[3s  B6  B6.V[3 ￿9  B6  B6.V[3 ~ 
%  %  %  % 
8  69.3 +  3.4  0.6 +  0.2  22.1  +  2.5  0.7 +- 0.2 
7  14.4 +  1.7  46.2 +  5.7  1.8 -+ 0.3  3.0 +  0.7 
2  8.1  --+ 0.4  47.1  +  3.6  6.5 +  0.8  14.0 +  0.5 
6  1.1  +  0.3  1.8 +  0.4  8.3 +- 0.4  11.5 --- 0.5 
Four B6 or B6.V[3  ~ mice aged 4 mo were analyzed individually.  Cells 
were stained with the indicated anti-V[3 mAbs and gated as described in 
Fig.  1.  Data  are  expressed as mean  •  SD.  Proportions of total liver 
NK1 + cells and CD4+NK1 + cells were 23.1%  +  2.1% and 14.7  + 
2.5% in B6 mice, and 19.9 --. 4.7% and 13.9 +- 3.8% in B6.V[3  a mice, 
respectively. 
about threefold as compared with normal age-matched B6 
mice (23.1  +  2.1% and 14.7  -+ 2.5%). The majority of liver 
CD4+NK1 + T  cells expressed  [~v (76.9  +-+- 2.7%),  although 
the intensity of staining was approximately fivefold lower than 
that  of lymph node  CD4 +  T  cells  (Fig.  2  B).  Surprisingly, 
liver CD4+NK1 + T  cells from the transgenic mice also ex- 
pressed endogenous V[38 (72.1  +  4.3%), V[37 (11.2 +  2.9%), 
or V[32  (3.2  --- 0.9%)  at similar frequencies as in nontrans- 
genic controls (Fig. 2  B  and Table 2).  Coexpression of [3  T 
(V[33)  and [~E (V[38)  on a  majority of liver CD4+NK1 + T 
cells was directly confirmed by four-color flow microfluo- 
rometry (Fig. 2  C).  Other [3rs,  such as VI36, were not seen 
in liver CD4+NK1 + T  cells ofTC1K-V[33 transgenic mice. 
The results obtained in TC1K-V[33 transgenic mice were 
basically confirmed in TC1K-V[38.1 transgenic mice (Fig. 2 
and Table 2).  In the latter mice, most lymph node CD4 § 
T  cells  expressed  [3T  (96.3  --+  1.8%)  but not  [3E, whereas 
liver CD4 +  NK1 +  T  cells  expressed  13  E at  levels close  to 
those of normal B6 mice (V[38.2, 47.6 +  2.3%; V[37, 19.5 + 
2.6%; V[~2, 7.5  +  1.7%).  Analysis of [3  T expression in liver 
CD4+NK1 + T  cells was complicated by the fact that KJ16 
mAb, which was used for staining, recognizes both V[38.1 
(~T) and V[38.2 ([3E). 
The  simultaneous  expression  of [3  T  and  ~E  on  a  high 
proportion  of liver CD4+NK1 +  T  cells  is  unexpected  in 
view  of the  fact  that  inhibition of endogenous rearrange- 
ment at the TCIK-[3 locus via allelic exclusion is usually ef- 
ficient in TCR  transgenic mice  (10).  However,  there  are 
several reported transgenic models where [3t genes are rear- 
ranged and expressed,  particularly under conditions of low 
levels of transgene expression (11)  and strong negative se- 
lection (12).  In the case of liver NK1 +  T  lineage cells, the 
expression of two  13 chains seems rather to reflect a strong 
positive selection for rare  cells that have endogenously re- 
arranged [3 chains with "permissive" V[3 domains. Indeed, 
[3E  expression  on  liver  NK1 +  T  cells  in  both  V[33-  and 
V[38.1-transgenic mice was  restricted  to V[38.2,  V[37,  and 
V~2.  Moreover,  the  relative  proportion  of  transgenic 
NK1 + T  cells expressing these endogenous V[3 domains was 
virtually identical to what is found in normal liver. Lack of 
allelic exclusion at the TC1L-[3 locus is not a general prop- 
erty  of liver NK1 +  T  cells,  since no  cells expressing two 
V[3 domains could be detected in normal mouse liver (data 
not shown). 
To formally test whether  NK1 +  T  cells are  able to  de- 
velop in the absence of appropriate V[3 expression, we crossed 
TCI<-V[33  and -V[38.1  transgenic mice  with  TCP,.-[3 -/- 
mice that have a homozygous deletion encompassing both 
CI3 domains (5). TC1L transgenic F1 mice were then back- 
crossed  to  TCP,-[3 -/-  mice,  and  the  F2  progeny  were 
typed for expression of the  TCR  transgenes as well as for 
endogenous V[3  expression. As shown in Fig.  3  and Table 
3,  no NK1 +  T  cells were  detectable in the liver of TCR- 
V[33  and -V138.1  transgenic TC1K-[3  -/-  mice, whereas  (as 
expected  from  Fig.  2)  liver NK1 +  T  cells expressing  en- 
Table 2.  Predominant Usage of Endogenous V~s among Liver CD4+ NK1 + T  Cells of TCR-~-Chain  Transgenic Mice 
Liver CD4+NK1 §  LN CD4 + 
V[3s  B6  V[33  T  V[38.1T  B6  V[33T  V[38.1T 
~T 
%  %  %  %  %  % 
3, 8.1-8.2  --  76.9 _+ 2.7  75.3 +  8.3  --  95.4 -  0.9  96.3 +  1.8 
8.1-8.3  69.8 +  0.9  72.1  +  4.3  --  21.4 +  1.5  3.1  +  0.5  -- 
8.2  55.0 +  2.4  ND  47.6 +  2.3  10.4 +  0.3  ND  3.6 +  0.9 
7  18.3 +  1.3  11.2 +  2.9  19.5 +  2.6  1.7 +  0.2  0.3 +  0.1  0.9 +  0.3 
2  8.6 _+ 0.4  3.2 -+ 0.9  7.5 -+ 1.7  6.1  +  0.3  0.2 +  0.1  1.2 _+ 0.2 
6  1.3 +- 0.1  1.0 +  0.2  1.1  __+ 0.3  8.6 +  0.3  0.4 +  0.2  1.7 +  0.5 
Three to four mice in each group were individually analyzed. Liver MNC and lymph node cells were stained with indicated anti-V [3 mAbs and 
gated as Fig. 2. Data are expressed as mean +  SD. Proportions of total liver NK1 + cells and CD4+NK1 + cells were 23.1 +  2.1% and 14.7 +  2.3% in 
B6 mice, 7.8 +  0.9% and 4.6 +  0.6% in V[~3 transgenic mice, and 8.1 -+ 0.7% and 5.2 -+ 0.6% in V[38.1 transgenic mice. ND, not done. 
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TCIk  13 +~-  littermate  controls.  In  contrast,  the  develop- 
ment of normal (NK1,1=)  T  cells in liver and lymph nodes 
of TCR-V~3-  or -V[~8.1-transgenic  mice was not affected 
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Figure  3.  Absence ofNK1 + T cells in the liver of V[33- and V[38.1- 
transgenic  mice lacking  endogenous  V[3 expression.  Liver MNCs from 
TCR transgenic or littermate control mice with ([3E  +/-) or without (13r  -/-) 
endogenous  Vt3 expression were stained with mAbs against TCP--I~ and 
NK1.1.  The proportion of cells in each quadrant is indicated. 
by  the  presence  or absence  of endogenous  V[3  expression 
(Fig.  3; data not shown).  These data formally establish that 
liver NK1 +  T  cells fail to  develop  unless  they  are  able  to 
express permissive V~ domains. 
In  conclusion,  we  show  here  that  the  development  of 
NK1 + T  cells in mouse liver is strictly dependent upon the 
utilization of a highly restricted susbset  of V[3  domains,  in- 
cluding  V[38,2,  V[37,  and  V{32.  In  contrast,  most  V[3- 
restricted responses of peripheral CD4 + or CD8 + T  cells to 
conventional  protein  antigens  in  vivo  are  more  plastic, 
since in the absence of a dominant epitope, T  cells express- 
ing other V[3 domains specific for previously cryptic or sub- 
dominant  epitopes appear  (13).  By analogy with these het- 
erogeneous  protein  antigen  responses,  it  seems  probable 
that  the  physiological  ligand  responsible  for  the  develop- 
ment  (and/or  expansion)  of liver NK1 +  T  cells in  vivo is 
highly  monomorphic.  In  this  regard,  it  has  recently  been 
Table  3.  Endogenous Vfl Expression Is Required  for NKI § T 
Cell Development in the Liver of TCR- Vfl3 and - VflS. 1 Transgenic 
Mice 
17.3  59.2 94.8  3.3 
..  20.5  "-..  1  .( 
Figure  2.  (/t)  Proportion of total and CD4+NK1 + T  cells in liver of 
V[~3- and V~8.1-transgenic  mice. Liver MNCs were stained as in Fig. 1 
A.  (/3) Transgenic  ([3T) and  endogenous  (BE) VI3  expression  on  liver 
CD4+NK1 + T  cells and lymph node CD4 + cells. V~ histograms were 
gated on CD4+NK1.1 + (liver) or CD4  + (lymph node)  cells. (C) Coex- 
pression of transgenic  (V[33) and endogenous  (V[38) TCR.-~ chains on 
hver CD4+NKI.1 §  cells from TCP,-VI33-transgenic  mice.  Four-color 
staining was performed  with mAbs against CD4, NKI.1, V~3, and V~8. 
Cytograms  are  gated  on CD4+NKI.1 + cells in liver or CD4+NKI.1 - 
cells in lymph node. 
Mouse  Endogenous VI3  TCR43 +  CD4 +  V[38.2 + 
strain  expression  NK1 +  NK 1  +  in CD4 
%  %  % 
V[33T  +  11.3,  12.3  3.5, 3.2  16.6,  11.9 
--  2.2,  2.2  0.4,  0.4  0.1,  0.2 
V~8.1T  +  12.5  +  1.0  3.9 +  0.7  13.6  +  2.7 
-  1.9  +  0.5  0.3  +  0.1  0.3  +  0.1 
Litter- 
mate  +  28.7  -  2.9  12.2  _.+ 2.4  30.7  +  2.2 
-  <1  <1  <1 
Two to  four mice in  each  group  were  analyzed  individually.  Liver 
MNCs were stained as in Fig. 2. Data are expressed as mean +  SD un- 
less  otherwise  indicated  (individual  mice).  Proportions  of  TCIq.- 
[3+NK1 + cells and CD4+NK1 + cells were estimated  in 8220- cells. 
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served TCR-ot chain consisting of VoL14-Jot281  rearrange- 
ments  with  fitde  (or  no) junctional  diversity (4).  Similar 
Vo~14-Jot281  rearrangements, which are believed to occur 
extrathymically (14),  are frequent  in other tissues, such  as 
bone marrow or liver (15). Interestingly, DN TCR-a/[3 + T 
cells  using  a  conserved Vo~24-JaQ  rearrangement  that  is 
highly homologous  to  the  mouse  VoL14-J(x281  sequence 
are expanded in the peripheral blood of many normal indi- 
viduals (4,  16), suggesting that a related (or identical) ligand 
is responsible for the selection of a distinct subset of T  cells 
in  both  mouse  and  humans,  The  precise  nature  of the 
ligand recognized by NK1 +  T  cells remains controversial. 
Since NK1 +  T  cells are present in TAP-l--deficient mice 
(17)  but fail to  develop in  [32m-deficient mice  (1-3),  it is 
likely that  the ligand should  consist  (at least in part)  of a 
TAP-independent [32m-associated molecule such as thymus 
leukemia antigen (18)  or CD1  (19).  Indeed, NK1 + T  cells 
and hybridomas have recently been shown to recognize fi- 
broblast stimulator cells infected with a vaccinia virus con- 
struct expressing the mouse CD1  gene (20). Moreover, cer- 
tain  constituents  of mycobacteria, such  as lipoglycans and 
mycotic acid, can be recognized by some human DN TCR- 
od[3  + cell lines in association with CDlb  (21, 22). Whether 
mouse NK1 + T  cells can also recognize CDl-associated my- 
cobacterial antigens remains, however, to be determined. 
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